tislelizumab

Tevimbra Approved for Some Patients With Unresectable or Metastatic ESCC

The FDA has approved tislelizumab for the first-line treatment of unresectable or metastatic esophageal squamous ...

MARCH 10, 2025

Tislelizumab Vies for First-Line Designation in Treatment of Advanced HCC

The checkpoint inhibitor tislelizumab might reasonably be considered a better choice for hepatocellular carcinoma ...

OCTOBER 20, 2023

Load more